This article discusses how pharmaceutical companies develop a winning strategy to defend their diverse portfolio of patents and the different strategies they implement. Finnegan partner James B. Monroe, speaks to claims covering chemical compounds, the difference in litigation strategies between generic and innovator companies, and the 30-month stay.
